



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

## NEOVACS ANNOUNCES ITS CLINICAL ADVISORY BOARD MEETING TO DESIGN THE PHASE III STUDY FOR IFN-K IN LUPUS

MEETING TO BE HELD IN PARIS, FEBRUARY 11<sup>TH</sup>

**Paris and Boston, January 31<sup>th</sup>, 2019 - 5:45 pm CET - Neovacs (Euronext Paris Growth Paris: ALNEV)**, leader in active immunotherapy for the treatment of auto-immune diseases, announces it has formed its Clinical Advisory Board (CAB) which will meet in Paris on the 11<sup>th</sup> of February. **Prof Frédéric Houssiau**, MD, PhD (Vice-Rector of the Health Sciences Sector, at the University Catholic of Louvain, Brussels, Belgium, formerly Head of the Rheumatology Department at the Cliniques Universitaires Saint-Luc in Brussels) will chair this CAB composed of multidisciplinary international medical experts in Lupus:

- *Pr Eric Morand*, MD, PhD, Head of the School of Clinical Sciences at Monash Health, Monash University and Head of the Monash Health Rheumatology Unit.
- *Pr Thomas Dörner*, MD, Professor of Rheumatology and Hemostaseology at Charité University Hospitals, Berlin,
- *Dr Katherine Thanou*, MD, Research Affiliate, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA
- *Dr Michael Tee*, MD, MHPED, MBA, Vice Chancellor, Medical Center Manila, Rheumatology Department, UP Manila College of Medicine
- *Dr Edsel Maurice Salvana*, MD, PhD, Director, Institute of Molecular Biology and Biotechnology, National Institutes of Health, University of the Philippines Manila, Philippines

This CAB under the Chairmanship of **Pr Frédéric Houssiau** will support Neovacs in the design of the Phase III study for IFN-K in Lupus, based on the results of the Phase IIb study.

### **About Neovacs**

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN $\alpha$ -Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

[www.neovacs.fr](http://www.neovacs.fr)

## **Contacts**

### **NEOVACS – Corporate Communication & Investor Relations**

**Charlène Masson**

+33 1 53 10 93 00

[cmasson@neovacs.com](mailto:cmasson@neovacs.com)

### **NEWCAP- Media**

**Annie-Florence Loyer**

+33 1 44 71 00 12 / + 33 6 88 20 35 59

[afloyer@newcap.fr](mailto:afloyer@newcap.fr)

**Léa Jacquin**

+33 1 44 71 20 41 / +33 6 58 14 84 66

[ljacquin@newcap.fr](mailto:ljacquin@newcap.fr)

### **ORPHEON FINANCE – Financial Communication and Investor Relations**

**James Palmer**

+33 7 60 92 77 74

[j.palmer@orpheonfinance.com](mailto:j.palmer@orpheonfinance.com)